ReLife International Medical Center in Beijing, China Reviews from Real Patients
About ReLife International Medical Center
ReLife International is a top Medical Center based in Beijing, China that combines Traditional Chinese Medicine with the latest breakthroughs in Stem Cell Therapy, Gene Therapy and Heart Surgery.
Anti Aging,Cancer Treatment,Chronic Diseases,ENT,Stem Cell Therapy Reviews in Beijing, China at ReLife International Medical Center
-
Anonymous
Check out the testimonial of a patient who had Traditional Chinese Medicine for Osteoarthritis in Beijing, China.
Dec 29 2021
-
Anonymous
Check out the testimonial of a patient who had Traditional Chinese Medicine for Ankylosing Spondylitis in Beijing, China.
Dec 12 2021
-
Anonymous
Mrs. T has been suffering primary gonadal failure since she was still a teenager. She was discharged from our center at the end of January. She stayed at ReLife for a whole month receiving our comprehensive treatment. For the first three weeks, our doctors applied both therapies of western medicine
Dec 18 2021 -
Anonymous
Visnja had successful Live Cell Therapy for ALS at ReLife International Medical Center in Beijing, China.
Dec 08 2021
-
Anonymous
Mrs. Jing suffered from premature ovarian failure until she underwent cell-based gene therapy and traditional Chinese medicine therapy for her premature ovarian failure at the ReLife International Medical Center in China.
Dec 09 2021
-
Anonymous
Mr. Kim underwent cell-based gene therapy for his ischemic heart disease at the ReLife International Medical Center in China.
Dec 12 2021
-
Anonymous
Mary, aged 3, underwent successful stem cell therapy, traditional Chinese medicine and supportive treatment for cerebral palsy at the ReLife International Medical Center in China.
Dec 19 2021
-
Anonymous
Mr. Zdravko had Mesenchymal Stem Cells Therapy and Traditional Chinese Medicine for Muscle Atrophy at ReLife International Medical Center.
Dec 04 2021
-
nosheen r
best ever response from the place and it would be among few preferred options
Oct 08 2018
